These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15361182)

  • 41. Health utilities in gynecological oncology and mastology in Germany.
    Hildebrandt T; Thiel FC; Fasching PA; Graf C; Bani MR; Loehberg CR; Schrauder MG; Jud SM; Hack CC; Beckmann MW; Lux MP
    Anticancer Res; 2014 Feb; 34(2):829-35. PubMed ID: 24511019
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In the Era of Cost-Effectiveness Analysis, Affordability Is a Limiting Factor for Patients' Access to Innovative Cancer Treatments.
    Aguiar PN; Adashek JJ; Roitberg F; Noia Barreto CM; Del Giglio A; Lopes GL
    Value Health Reg Issues; 2019 Dec; 20():47-50. PubMed ID: 30856543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessing economics of treatments for gynecological cancer where clinical effectiveness meets value for money.
    Stoykova B; Dowie R; Kitchener HC
    Int J Gynecol Cancer; 2004; 14(5):762-71. PubMed ID: 15361182
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health economic evaluation of non-melanoma skin cancer and actinic keratosis.
    Higashi MK; Veenstra DL; Langley PC
    Pharmacoeconomics; 2004; 22(2):83-94. PubMed ID: 14731050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical economics in clinical trials: the measurement of cost and outcomes in the assessment of clinical services through clinical trials.
    Schulman KA; Ohishi A; Park J; Glick HA; Eisenberg JM
    Keio J Med; 1999 Mar; 48(1):1-11. PubMed ID: 10206013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment.
    Neumann PJ
    J Clin Psychiatry; 1999; 60 Suppl 3():9-14; discussion 15. PubMed ID: 10073371
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The complex interface between economy and healthcare: An introductory overview for clinicians.
    Ottolini FL; Buggio L; Somigliana E; Vercellini P
    Eur J Intern Med; 2016 Dec; 36():1-6. PubMed ID: 27577606
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrating economic analysis into cancer clinical trials: the National Cancer Institute-American Society of Clinical Oncology Economics Workbook.
    J Natl Cancer Inst Monogr; 1998; (24):1-28. PubMed ID: 9704318
    [No Abstract]   [Full Text] [Related]  

  • 51. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.